Promising sarcoma study pulled before starting
NCT ID NCT06116578
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 21 times
Summary
This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS). It aimed to test if adding a DNA repair inhibitor (olaparib) to immunotherapy (pembrolizumab) before surgery could boost the immune response. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94800, France
Conditions
Explore the condition pages connected to this study.